Analysts Offer Predictions for STOK Q1 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.53) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $47.00 price target on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.54) EPS.

STOK has been the subject of several other reports. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday. Chardan Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Stoke Therapeutics has an average rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Trading Down 6.9 %

NASDAQ STOK opened at $8.26 on Thursday. The company has a market capitalization of $437.51 million, a price-to-earnings ratio of -3.93 and a beta of 0.99. The stock’s 50 day moving average is $9.50 and its two-hundred day moving average is $11.51. Stoke Therapeutics has a 1-year low of $5.60 and a 1-year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million.

Hedge Funds Weigh In On Stoke Therapeutics

Several large investors have recently bought and sold shares of STOK. Barclays PLC grew its position in shares of Stoke Therapeutics by 145.3% during the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after acquiring an additional 47,239 shares during the period. Geode Capital Management LLC grew its stake in Stoke Therapeutics by 9.7% in the 3rd quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after buying an additional 76,661 shares in the last quarter. State Street Corp raised its holdings in shares of Stoke Therapeutics by 8.6% during the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after buying an additional 137,145 shares in the last quarter. RTW Investments LP lifted its holdings in shares of Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after acquiring an additional 427,447 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Stoke Therapeutics by 1,589.7% during the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after buying an additional 71,647 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.